Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
Song
Jonathan C
JC
Doheny Eye Institute/Los Angeles County and USC-LAC Medical Center, USA.
McDonnell
Peter J
PJ
Gordon
Erlinda M
EM
Hall
Frederick L
FL
Anderson
W French
WF
D000293:Adolescent; D000328:Adult; D000368:Aged; D003318:Corneal Opacity / Q000628:therapy*; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008875:Middle Aged; D012190:Retroviridae
C534702:CCNG1 protein, human; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins